Iovance Biotherapeutics Inc (IOVA)

$3.56 -0.14 (-3.78%)
Market Cap 1.65B
Revenue (ttm) 263.50M
Net Income (ttm) -390.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.38%
Debt to Equity Ratio 0.00
Volume 20,983,602
Avg Vol 16,758,256
Day's Range N/A - N/A
Shares Out 446.50M
Stochastic %K 31%
Beta 0.69
Analysts Strong Sell
Price Target $8.18

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
AwasomeStrangerI
AwasomeStrangerI May. 13 at 2:17 PM
$IOVA Freaking REPL doubles on stupid speculation and here we are stuck in a mud with the company running ATM nonstop no matter the price. Frustrating!
2 · Reply
ianleung
ianleung May. 13 at 2:10 PM
$IOVA we are traded like an orphan now😮‍💨
0 · Reply
5thElement
5thElement May. 13 at 1:59 PM
$IOVA $REPL bogus rally, but I am glad for the investors. Trump should just approve it. We all know how dirty the politics are.
0 · Reply
BigGainTom
BigGainTom May. 13 at 1:56 PM
$REPL $IOVA Nice rallies!
0 · Reply
Iovabulllover
Iovabulllover May. 13 at 1:51 PM
Opened a small position in $AQST after taking profits from $IOVA Hope tomorrow goes well
2 · Reply
jconnors7
jconnors7 May. 13 at 1:47 PM
$IOVA ”A rising tide lifts all ships.” Meaning: i own both REPL and IOVA and plan on both being successful and both going much higher. Why people bash one or the other here I do bot know. I own AI, semis, crypto. They all go up together when supported Why cant IOVA and REPL. “A rising tide lifts all ships.”
0 · Reply
Lilwopjob
Lilwopjob May. 13 at 1:47 PM
$IOVA via claude
2 · Reply
LostChang3
LostChang3 May. 13 at 1:43 PM
$IOVA i want this to work but I'm also tired of being lied to. They are not working on non-dilutive financing. They 100% would have had it now if that was actually a goal
0 · Reply
Jarvis7424
Jarvis7424 May. 13 at 1:43 PM
$IOVA just pinned at $3.5
0 · Reply
BioCrazy1
BioCrazy1 May. 13 at 1:28 PM
$IOVA This is the professional way to move “Rothbaum/BlackRock-sized” money without everyone else front-running it. 6% of the companies shares traded hands yesterday after hours. 81 % of yesterday's volume was off exchange dark pool.
2 · Reply
Latest News on IOVA
Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

2026-05-08T00:11:03.000Z - 5 days ago

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

2026-05-07T13:16:25.000Z - 6 days ago

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

2026-05-07T13:15:56.000Z - 6 days ago

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

2026-05-07T13:14:41.000Z - 6 days ago

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 6 days ago

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

May 7, 2026, 7:05 AM EDT - 6 days ago

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Apr 27, 2026, 8:01 AM EDT - 16 days ago

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Apr 17, 2026, 5:15 PM EDT - 25 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Replimune CRL positive for Iovance in near-term, says Chardan

2026-04-10T17:43:13.000Z - 4 weeks ago

Replimune CRL positive for Iovance in near-term, says Chardan

REPL

Unusually active option classes on open April 10th

2026-04-10T13:40:33.000Z - 4 weeks ago

Unusually active option classes on open April 10th

ALAB AMC AMD AMZN EOSE FSLY KLAR

Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 9:30 AM EDT - 2 months ago

Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Iovance Biotherapeutics call volume above normal and directionally bullish

2026-03-06T19:45:13.000Z - 2 months ago

Iovance Biotherapeutics call volume above normal and directionally bullish

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

2026-03-05T12:39:20.000Z - 2 months ago

Iovance Biotherapeutics price target raised to $4 from $2 at UBS

Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:50 AM EST - 2 months ago

Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Iovance Biotherapeutics to Present at Upcoming Conferences

Feb 26, 2026, 8:00 AM EST - 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

2026-02-25T14:14:16.000Z - 2 months ago

Iovance Biotherapeutics price target raised to $4 from $3 at Baird

Iovance Biotherapeutics price target raised to $11 from $10 at Barclays

2026-02-25T10:26:51.000Z - 2 months ago

Iovance Biotherapeutics price target raised to $11 from $10 at Barclays

Iovance upgraded to Outperform from Market Perform at Citizens

2026-02-25T09:45:12.000Z - 2 months ago

Iovance upgraded to Outperform from Market Perform at Citizens

Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

2026-02-24T22:30:40.000Z - 2 months ago

Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan

Unusually active option classes on open February 24th

2026-02-24T14:40:27.000Z - 2 months ago

Unusually active option classes on open February 24th

AMD CEG F HD HPQ IBM TEVA

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 2 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)

2026-02-24T12:19:34.000Z - 2 months ago

Iovance Biotherapeutics reports Q4 EPS (18c), consensus (18c)

Iovance Biotherapeutics announces results from trial for TIL cell therapy

2026-02-24T12:10:31.000Z - 2 months ago

Iovance Biotherapeutics announces results from trial for TIL cell therapy

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Feb 24, 2026, 7:00 AM EST - 2 months ago

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Feb 24, 2026, 7:00 AM EST - 2 months ago

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Feb 11, 2026, 4:05 PM EST - 3 months ago

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Feb 5, 2026, 5:15 PM EST - 3 months ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

2026-02-05T12:55:28.000Z - 3 months ago

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Iovance Biotherapeutics price target raised to $10 from $9 at Barclays

2025-12-17T11:00:42.000Z - 5 months ago

Iovance Biotherapeutics price target raised to $10 from $9 at Barclays

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Iovance Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:00 AM EDT - 8 months ago

Iovance Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Iovance Biotherapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 8:00 AM EDT - 8 months ago

Iovance Biotherapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 18, 2025, 4:15 PM EDT - 9 months ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Aug 7, 2025, 4:01 PM EDT - 9 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 23, 2025, 12:08 PM EDT - 10 months ago

Here's why Iova stock surged 32% today and why the rally might not be over

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 15, 2025, 7:30 AM EDT - 10 months ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 9:04 AM EDT - 10 months ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 14, 2025, 7:30 AM EDT - 10 months ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 10 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 10, 2025, 8:18 AM EDT - 10 months ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 28, 2025, 7:46 AM EDT - 11 months ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 20, 2025, 9:07 AM EDT - 11 months ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 18, 2025, 8:38 AM EDT - 11 months ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 11 months ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Iovance Biotherapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 1:20 PM EDT - 11 months ago

Iovance Biotherapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Iovance Biotherapeutics Transcript: AGM 2025

Jun 10, 2025, 11:00 AM EDT - 1 year ago

Iovance Biotherapeutics Transcript: AGM 2025

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

Jun 10, 2025, 8:47 AM EDT - 1 year ago

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

AwasomeStrangerI
AwasomeStrangerI May. 13 at 2:17 PM
$IOVA Freaking REPL doubles on stupid speculation and here we are stuck in a mud with the company running ATM nonstop no matter the price. Frustrating!
2 · Reply
ianleung
ianleung May. 13 at 2:10 PM
$IOVA we are traded like an orphan now😮‍💨
0 · Reply
5thElement
5thElement May. 13 at 1:59 PM
$IOVA $REPL bogus rally, but I am glad for the investors. Trump should just approve it. We all know how dirty the politics are.
0 · Reply
BigGainTom
BigGainTom May. 13 at 1:56 PM
$REPL $IOVA Nice rallies!
0 · Reply
Iovabulllover
Iovabulllover May. 13 at 1:51 PM
Opened a small position in $AQST after taking profits from $IOVA Hope tomorrow goes well
2 · Reply
jconnors7
jconnors7 May. 13 at 1:47 PM
$IOVA ”A rising tide lifts all ships.” Meaning: i own both REPL and IOVA and plan on both being successful and both going much higher. Why people bash one or the other here I do bot know. I own AI, semis, crypto. They all go up together when supported Why cant IOVA and REPL. “A rising tide lifts all ships.”
0 · Reply
Lilwopjob
Lilwopjob May. 13 at 1:47 PM
$IOVA via claude
2 · Reply
LostChang3
LostChang3 May. 13 at 1:43 PM
$IOVA i want this to work but I'm also tired of being lied to. They are not working on non-dilutive financing. They 100% would have had it now if that was actually a goal
0 · Reply
Jarvis7424
Jarvis7424 May. 13 at 1:43 PM
$IOVA just pinned at $3.5
0 · Reply
BioCrazy1
BioCrazy1 May. 13 at 1:28 PM
$IOVA This is the professional way to move “Rothbaum/BlackRock-sized” money without everyone else front-running it. 6% of the companies shares traded hands yesterday after hours. 81 % of yesterday's volume was off exchange dark pool.
2 · Reply
Charlie_Omaha
Charlie_Omaha May. 13 at 1:20 PM
$IOVA We trade nearly 20 million shares a day, either we drop 4-5% without effort in first half hour and spend rest of the day what 4-5 penny range. Always. Forever and ever. 90% trading days are negative.
0 · Reply
dogbone98
dogbone98 May. 13 at 1:18 PM
$IOVA Did everyone see those PPI numbers? Holy sheet. We're looking at rate increases instead of cuts unless Iran and tariff stupidity stops right now. 7.4% Y/Y for Food & Goods is unbelievable.
2 · Reply
Magnificient
Magnificient May. 13 at 1:10 PM
$IOVA when we expect next catalyst? Australia Approval and then?
0 · Reply
Ixnay84
Ixnay84 May. 13 at 1:09 PM
$IOVA The higgest I saw for a while... interpret as you wish...
2 · Reply
Flyingkitty
Flyingkitty May. 13 at 12:57 PM
$IOVA Don't let speculation affect your long term focus... Cheers !
0 · Reply
kaoz
kaoz May. 13 at 12:55 PM
$IOVA
0 · Reply
BKEBurgy
BKEBurgy May. 13 at 12:53 PM
$IOVA it’s a beautiful Wednesday, let’s have a fucking day god damnit!!
1 · Reply
Charlie_Omaha
Charlie_Omaha May. 13 at 12:35 PM
$IOVA 100 ACT, 10 a year on average. 1000 infusions, about 500-550 million revenue. How incompetent Fred got to be to botch this once-in-a-life-time opportunity? Seriously criminal incompetence.
1 · Reply
Fire_Truck
Fire_Truck May. 13 at 12:30 PM
$IOVA BO isn't going to happen without lung approval. I think it's safe to say.
1 · Reply
Charlie_Omaha
Charlie_Omaha May. 13 at 12:27 PM
$IOVA Under capable leadership of Fred and astute guidance of legendary investor Wayne, we are up 2 pennies. FDA approved product with 350 million revenue and three highly first-in-clasd therapies. Wow.... Amazing management. The best ever. /S
1 · Reply
calbucs
calbucs May. 13 at 10:58 AM
$IOVA One day we will wake up to a BO with Lung approval , $50 plus but that day may not come for a year . But it’s coming
5 · Reply
SIMBATECH
SIMBATECH May. 13 at 10:52 AM
$IOVA why the stock sits at 3.5….Fred. heres why: maintenance excuse causes 60% reduction in rev 2025 nomore ATM usage. not true q1 forecast will be out shortly….no release and now we know rev miss by 5% You can not trust the CEO and thats the problem
2 · Reply